Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Moderna, Inc. - Common Stock (NQ: MRNA )

35.53 +1.80 (+5.34%)
Streaming Delayed Price Updated: 4:00 PM EST, Feb 21, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Moderna, Inc. - Common Stock

< Previous 1 2
...
28 29 30 31 32 33 34 35 36
...
99 100 Next >
Nvidia, United Airlines, Moderna, Lucid, Bank Of America: Why These Five Stocks Are On Investors' Horizons Today
U.S. stocks exhibited a mixed performance as the trading day drew to a close, with the Nasdaq Composite taking a dip of around 30 points. 
Via Benzinga
Topics Stocks
Exposures US Equities
What's Going On With Moderna Stock?
Moderna Inc (NASDAQ: MRNA) shares are continuing to trade lower Tuesday following Pfizer Inc's (NYSE: PFE) warning about 
Via Benzinga
Do These 5 Words From Pfizer Mean Trouble for Novavax?
Coronavirus vaccine sales could represent recurrent annual revenue for Novavax and rivals. 
Via The Motley Fool
Exposures COVID-19
Healthcare Portfolio Focus Stocks
The macro news has been a steady headwind with rising rates offering 5% risk-free treasury yields. 
Via Talk Markets
Check Out What Whales Are Doing With MRNA
Via Benzinga
Moderna Unusual Options Activity For October 12
Via Benzinga
2 Top Biotech Stocks to Buy Right Now
Both companies are known innovators. 
Via The Motley Fool
These 2 Top Stocks Are Screaming Buys Right Now
These stocks are dirt cheap today. 
Via The Motley Fool
Moderna, BioNTech Lead Covid Sell-Off After Pfizer Slashes Its Outlook By $9 Billion
Pfizer cut about $9 billion from its sales expectations for Covid products this year. 
Via Investor's Business Daily
Exposures COVID-19
Novavax Faces Setback, European Authority Delays Decision On Variant-Tailored COVID-19 Vaccine
Novavax Inc (NASDAQ: NVAX) faces a setback as the European Medicines Agency (EMA) delays a decision on its variant-tailored COVID-19 vaccine.  
Via Benzinga
Exposures COVID-19
The 10 Most Shorted Stocks Include 3 Tesla Rivals, But Not TSLA
Some big 2023 winners are shorted heavily, including two AI plays. 
Via Investor's Business Daily
Topics Artificial Intelligence
Exposures Artificial Intelligence
BioNTech, Moderna And Other Big Stocks Moving Lower In Monday's Pre-Market Session
U.S. stock futures traded higher this morning on Monday. Here are some big stocks recording losses in today’s pre-market trading session. 
Via Benzinga
Is Novavax Stock a Buy Now?
Is this company just a pandemic stock? 
Via The Motley Fool
Don’t Hold On: 7 Stocks to Sell Before 2024
Consider it best to jettison these seven stocks to sell from your portfolio, between now and the end of 2023. 
Via InvestorPlace
1 Artificial Intelligence Stock to Buy Hand Over Fist in October and 1 to Avoid
One of these players could win in AI -- and in the healthcare market, in general. 
Via The Motley Fool
Topics Artificial Intelligence
Exposures Artificial Intelligence
Moderna to Report Third Quarter 2023 Financial Results on Thursday, November 2, 2023
Via ACCESSWIRE
3 Stocks That Are Down Big, But Are Due to Fall Much Further
While the search for falling stocks is an easy one, these are the ones that might not get up from the mat. 
Via InvestorPlace
The COVID Vaccine Market Is Changing Dramatically. Do Vaccine Stocks Still Make Good Investments?
Vaccine revenue may have slipped but could still represent billions of dollars for these companies. 
Via The Motley Fool
Exposures COVID-19
Big Pharma Could Transform Into BioTech Pharma
As the word itself says, biotechnology is simply technology based on biology. It uses the knowledge of cellular and biomolecular processes to develop technologies that improve our lives and overall... 
Via Benzinga
3 Shaky Stocks to Sell in October Before It’s Too Late
Investors who are concerned about the direction of the market moving forward should sell these three vulnerable stocks now. 
Via InvestorPlace
Timing Favors Novavax's Delayed Approval, Arrival Ahead of Peak COVID Vaccine Demand
Last week, Novavax Inc (NASDAQ: NVAX) received FDA authorization for its updated COVID-19 vaccine, targeting the omicron subvariant XBB.1.5 in  
Via Benzinga
Exposures COVID-19 Product Safety
Privatized Vaccine Distribution Sparks Confusion, Payment Challenges
As the rollout of the updated COVID-19 vaccine progresses, some individuals have been surprised by requests for upfront payments ranging from $150 to $200.  
Via Benzinga
Exposures COVID-19
Intuit, Nordstrom And 2 Other Stocks Insiders Are Selling
The Nasdaq 100 closed higher by around 250 points on Friday. Investors, meanwhile, focused on some notable insider trades. 
Via Benzinga
3 Pharma Stocks to Dump Before the Damage Is Done
There's never a shortage of pharma stocks to sell due to the nature of the sector, especially when compounded by current fears. 
Via InvestorPlace
Rockwell’s Heitkoetter Talks Options Strategies, “Wheel Options,” Volatility, & Value Stocks
In this video, Markus Heitkoetter, CEO of Rockwell Trading Services, explains how he began investing as a high schooler with one share of Volkswagen. 
Via Talk Markets
Rule Breaker Investing's "Market Cap Game Show" Rolls On
This episode required a tiebreaker. 
Via The Motley Fool
This Could be Novavax's Big Opportunity
Novavax has lagged behind bigger rivals in the vaccine market. 
Via The Motley Fool
3 Undervalued Healthcare Stocks to Watch as Sector Struggles
As the healthcare sector slumps, several major stocks, including Zimmer Biomet, Moderna, and Illumina, appear undervalued in contrast to their intrinsic worth. 
Via MarketBeat
Did Moderna Just Jump Ahead of Rivals in a Potential Billion-Dollar Market?
Moderna, Pfizer, and Novavax all are working on combined vaccine candidates. 
Via The Motley Fool
Small Biotech Promosome Drops Lawsuit Against Pfizer, BioNTech in COVID-19 Vaccine Patent Dispute
Biotech firm Promosome has agreed to end the lawsuit, which accused the COVID-19 vaccine manufacturers, Pfizer Inc (NYSE: PFE) and BioNTech SE (NASDAQ: BNTX), of patent infrin 
Via Benzinga
Topics Intellectual Property Lawsuit
Exposures COVID-19 Financial Intellectual Property
< Previous 1 2
...
28 29 30 31 32 33 34 35 36
...
99 100 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.